DE69533693D1 - Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten - Google Patents

Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten

Info

Publication number
DE69533693D1
DE69533693D1 DE69533693T DE69533693T DE69533693D1 DE 69533693 D1 DE69533693 D1 DE 69533693D1 DE 69533693 T DE69533693 T DE 69533693T DE 69533693 T DE69533693 T DE 69533693T DE 69533693 D1 DE69533693 D1 DE 69533693D1
Authority
DE
Germany
Prior art keywords
adjuvant
lipid vesicles
vaccines containing
paucilamellar lipid
containing paucilamellar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533693T
Other languages
English (en)
Other versions
DE69533693T2 (de
Inventor
Craig D Wright
Donald F H Wallach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novavax Inc
Original Assignee
Micro Pak Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micro Pak Inc filed Critical Micro Pak Inc
Publication of DE69533693D1 publication Critical patent/DE69533693D1/de
Application granted granted Critical
Publication of DE69533693T2 publication Critical patent/DE69533693T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE69533693T 1994-02-24 1995-01-11 Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten Expired - Lifetime DE69533693T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20134694A 1994-02-24 1994-02-24
US201346 1994-02-24
PCT/US1995/000475 WO1995022989A1 (en) 1994-02-24 1995-01-11 Vaccines containing paucilamellar lipid vesicles as immunological adjuvants

Publications (2)

Publication Number Publication Date
DE69533693D1 true DE69533693D1 (de) 2004-12-02
DE69533693T2 DE69533693T2 (de) 2005-12-22

Family

ID=22745474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533693T Expired - Lifetime DE69533693T2 (de) 1994-02-24 1995-01-11 Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten

Country Status (8)

Country Link
EP (1) EP0746338B1 (de)
JP (1) JP3836874B2 (de)
AT (1) ATE280585T1 (de)
AU (1) AU1566095A (de)
BR (1) BR9506885A (de)
CA (1) CA2183435C (de)
DE (1) DE69533693T2 (de)
WO (1) WO1995022989A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
NZ508013A (en) * 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1467771B1 (de) * 2001-11-14 2008-04-16 Novavax, Inc. Mycobakterieller impfstoff
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
SG153871A1 (en) * 2004-06-25 2009-07-29 Id Biomedical Corp Quebec Compositions and methods for treating neurological disorders
EP2669002A1 (de) * 2005-01-28 2013-12-04 Japan Science and Technology Agency Molekulares, für Phasenübergang durch Dehydrierungskondensation fähiges Aggregat und Verfahren zum Phasenübergang davon
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
DE602006020738D1 (de) * 2005-08-01 2011-04-28 Hisamitsu Pharmaceutical Co Adjuvans oder pharmazeutische zubereitung zur transdermalen oder transmukosalen verabreichung
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
FR2906141B1 (fr) * 2006-09-26 2010-12-10 St Hubert Structure uni-ou multivesciculaire enfermant une phase hydrophobe.
US20100047327A1 (en) * 2007-01-31 2010-02-25 Tetsuji Kuwahara Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CN101827613A (zh) 2007-09-27 2010-09-08 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
EP2296696B1 (de) 2008-06-05 2014-08-27 ImmunoVaccine Technologies Inc. Zusammensetzungen mit liposomen, einem antigen, einem polynucleotid und einem träger mit einer kontinuierlichen phase einer hydrophoben substanz
AU2012321022B2 (en) 2011-10-06 2017-03-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
JP2014040396A (ja) * 2012-08-23 2014-03-06 Chemo-Sero-Therapeutic Research Institute 脂質異常症治療薬を含有するアジュバント組成物
JP6114401B2 (ja) 2013-10-31 2017-04-12 久光製薬株式会社 アジュバント組成物、これを含むアジュバント製剤、及びキット
GR1008481B (el) * 2013-12-05 2015-05-12 Συμβουλοι Αναπτυξης Πωλησεων Επε, Μεθοδος εγκλωβισμου φυτικων ελαιων και ιδιαιτερα ελαιολαδου με τη χρηση εξειδικευμενων βρωσιμων λιποσωματων, χωρις φωσφολιπιδια, για εφαρμογες στον τομεα τροφιμων και ειδικοτερα προϊοντων αλλαντοποιιας, γαλακτοκομικων και ιχθυοσκευασματων
WO2023022384A1 (ko) * 2021-08-17 2023-02-23 한국과학기술원 면역 유도용 다층 소포체, 이를 포함하는 면역 유도용 약학 조성물 및 면역 유도용 다층 소포체의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
US5147723A (en) * 1987-07-28 1992-09-15 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
US5234767A (en) * 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5032457A (en) * 1988-03-03 1991-07-16 Micro Vesicular Systems, Inc. Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
CA2153780C (en) * 1993-01-15 2004-04-13 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction

Also Published As

Publication number Publication date
AU1566095A (en) 1995-09-11
CA2183435C (en) 2008-05-13
JPH10500662A (ja) 1998-01-20
EP0746338A1 (de) 1996-12-11
DE69533693T2 (de) 2005-12-22
CA2183435A1 (en) 1995-08-31
EP0746338A4 (de) 2001-08-22
EP0746338B1 (de) 2004-10-27
BR9506885A (pt) 1997-08-19
WO1995022989A1 (en) 1995-08-31
JP3836874B2 (ja) 2006-10-25
ATE280585T1 (de) 2004-11-15

Similar Documents

Publication Publication Date Title
DE69533693D1 (de) Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
EP1333858B8 (de) Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
OA09800A (en) Vaccine compositions containing liposomes.
WO1997049423A3 (en) Liposomal influenza vaccine composition and method
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
EP1955709A3 (de) Adjuvanzverbindungen zur Verbesserung von Immunreaktionen auf Polynukleotid-basierten Impfstoffen
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
FI875015A (fi) Vaccin mot juverinflammation.
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
BRPI0412913A (pt) meio para tratamento de infecções por leishmaniose
MX9603547A (es) Vacunas que contienen vesiculas de lipido paucilamelar como adyuvantes inmunologicos.
WO2001015727A3 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Dietzschold et al. Synthesis of an antigenic determinant of the HSV gD that stimulates the induction of virus-neutralizing antibodies and confers protection against a lethal challenge of HSV.
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen
BG51003A1 (en) Method for preparing of subunit liposome grippe vaccine

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVAVAX INC.(N.D.GES.D.STAATES DELAWARE), COLUMBIA

8364 No opposition during term of opposition